181 related articles for article (PubMed ID: 27226843)
1. Novel methodology for pharmaceutical expenditure forecast.
Vataire AL; Cetinsoy L; Aballéa S; Rémuzat C; Urbinati D; Kornfeld Å; Mzoughi O; Toumi M
J Mark Access Health Policy; 2014; 2():. PubMed ID: 27226843
[TBL] [Abstract][Full Text] [Related]
2. EU pharmaceutical expenditure forecast.
Urbinati D; Rémuzat C; Kornfeld Å; Vataire AL; Cetinsoy L; Aballéa S; Mzoughi O; Toumi M
J Mark Access Health Policy; 2014; 2():. PubMed ID: 27226837
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical expenditure forecast model to support health policy decision making.
Rémuzat C; Urbinati D; Kornfeld Å; Vataire AL; Cetinsoy L; Aballéa S; Mzoughi O; Toumi M
J Mark Access Health Policy; 2014; 2():. PubMed ID: 27226830
[TBL] [Abstract][Full Text] [Related]
4. Key drivers for market penetration of biosimilars in Europe.
Rémuzat C; Dorey J; Cristeau O; Ionescu D; Radière G; Toumi M
J Mark Access Health Policy; 2017; 5(1):1272308. PubMed ID: 28265349
[No Abstract] [Full Text] [Related]
5. Estimating the budget impact of orphan drugs in Sweden and France 2013-2020.
Hutchings A; Schey C; Dutton R; Achana F; Antonov K
Orphanet J Rare Dis; 2014 Feb; 9():22. PubMed ID: 24524281
[TBL] [Abstract][Full Text] [Related]
6. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
Schey C; Milanova T; Hutchings A
Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
[TBL] [Abstract][Full Text] [Related]
7. An analysis of orphan medicine expenditure in Europe: is it sustainable?
Mestre-Ferrandiz J; Palaska C; Kelly T; Hutchings A; Parnaby A
Orphanet J Rare Dis; 2019 Dec; 14(1):287. PubMed ID: 31829218
[TBL] [Abstract][Full Text] [Related]
8. Overview of external reference pricing systems in Europe.
Rémuzat C; Urbinati D; Mzoughi O; El Hammi E; Belgaied W; Toumi M
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123181
[TBL] [Abstract][Full Text] [Related]
9. Use of budget savings from patent expiration of cancer drugs to improve affordability and accessibility.
Lee SM; Kim HJ; Suh D; Joung KI; Kim ES; Back HJ; Kwon JY; Park MJ; Suh DC
BMC Health Serv Res; 2021 Feb; 21(1):126. PubMed ID: 33549099
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia.
Tesar T; Golias P; Masarykova L; Kawalec P; Inotai A
Front Pharmacol; 2021; 12():795002. PubMed ID: 34966285
[No Abstract] [Full Text] [Related]
11. Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure.
Vogler S; Schneider P; Zuba M; Busse R; Panteli D
Front Pharmacol; 2021; 12():625296. PubMed ID: 34248615
[No Abstract] [Full Text] [Related]
12. Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries.
Kawalec P; Stawowczyk E; Tesar T; Skoupa J; Turcu-Stiolica A; Dimitrova M; Petrova GI; Rugaja Z; Männik A; Harsanyi A; Draganic P
Front Pharmacol; 2017; 8():288. PubMed ID: 28642700
[No Abstract] [Full Text] [Related]
13. Measuring performance in off-patent drug markets: a methodological framework and empirical evidence from twelve EU Member States.
Kanavos P
Health Policy; 2014 Nov; 118(2):229-41. PubMed ID: 25201433
[TBL] [Abstract][Full Text] [Related]
14. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
Chen B; Nagai S; Armitage JO; Witherspoon B; Nabhan C; Godwin AC; Yang YT; Kommalapati A; Tella SH; DeAngelis C; Raisch DW; Sartor O; Hrushesky WJ; Ray PS; Yarnold PR; Love BL; Norris LB; Knopf K; Bobolts L; Riente J; Luminari S; Kane RC; Hoque S; Bennett CL
Oncologist; 2019 Apr; 24(4):537-548. PubMed ID: 30842244
[TBL] [Abstract][Full Text] [Related]
15. European healthcare policies for controlling drug expenditure.
Ess SM; Schneeweiss S; Szucs TD
Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
[TBL] [Abstract][Full Text] [Related]
16. Potential impact of policy regulation and generic competition on sales of cholesterol lowering medication, antidepressants and acid blocking agents in Belgium.
Fraeyman J; Van Hal G; De Loof H; Remmen R; De Meyer GR; Beutels P
Acta Clin Belg; 2012; 67(3):160-71. PubMed ID: 22897063
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of price competition in Italian pharmaceutical off-patent market.
Perna S; Cangini A; Marini R; Guerrizio MA; Da Cas R; Traversa G; Trotta F
Front Med (Lausanne); 2022; 9():1045374. PubMed ID: 36523775
[TBL] [Abstract][Full Text] [Related]
18. Projecting expenditure on medicines in the UK NHS.
O'Neill P; Mestre-Ferrandiz J; Puig-Peiro R; Sussex J
Pharmacoeconomics; 2013 Oct; 31(10):933-57. PubMed ID: 24037786
[TBL] [Abstract][Full Text] [Related]
19. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
[TBL] [Abstract][Full Text] [Related]
20. Drug Policy in the Czech Republic.
Skoupá J
Value Health Reg Issues; 2017 Sep; 13():55-58. PubMed ID: 29073989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
